These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11497396)

  • 1. Clinical benefits of lenograstim in patients with neutropenia due to chemotherapy for multiple myeloma (MM).
    Takagi T; Sawamura M; Sezaki T; Kashimura M; Tsuchiya J; Hotta T; Ogawa N; Hirashima K
    Support Care Cancer; 2001 Jul; 9(5):397-9. PubMed ID: 11497396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.
    Gisselbrecht C; Haioun C; Lepage E; Bastion Y; Tilly H; Bosly A; Dupriez B; Marit G; Herbrecht R; Deconinck E; Marolleau JP; Yver A; Dabouz-Harrouche F; Coiffier B; Reyes F
    Leuk Lymphoma; 1997 Apr; 25(3-4):289-300. PubMed ID: 9168439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical evaluation of rhG-CSF in patients with neutropenia induced by chemotherapy for multiple myeloma].
    Togawa A; Mizoguchi H; Toyama K; Urabe A; Ohasi Y; Takaku F
    Rinsho Ketsueki; 2000 Feb; 41(2):115-22. PubMed ID: 10723240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic analysis of lenograstim in the correction of neutropenia following chemotherapy for non-Hodgkin's lymphoma.
    Souêtre E; Qing W
    Pharmacoeconomics; 1994; 6 Suppl 2():36-43. PubMed ID: 10172484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a new formulation of lenograstim (recombinant glycosylated human granulocyte colony-stimulating factor) containing gelatin for the treatment of neutropenia after consolidation chemotherapy in patients with acute myeloid leukemia.
    Takeshita A; Saito H; Toyama K; Horiuchi A; Kuriya S; Furusawa S; Tsuruoka N; Takiguchi T; Matsuda T; Utsumi M; Shiku H; Matsui T; Egami K; Tamura K; Ohno R
    Int J Hematol; 2000 Feb; 71(2):136-43. PubMed ID: 10745623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy with MCNU, vindesine, melphalan, and prednisolone (MCNU-VMP therapy) in induction therapy for multiple myeloma. Japan Myeloma Study Group.
    Imamura Y; Takagi T; Yawata Y; Nishinarita S; Kosaka M; Mikuni C; Takatsuki K; Sezaki T; Mori M; Tsuchiya J
    Int J Hematol; 1994 Feb; 59(2):113-23. PubMed ID: 8018904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
    Bui BN; Chevallier B; Chevreau C; Krakowski I; Peny AM; Thyss A; Maugard-Louboutin C; Cupissol D; Fargeot P; Bonichon F
    J Clin Oncol; 1995 Oct; 13(10):2629-36. PubMed ID: 7595717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.
    Chevallier B; Chollet P; Merrouche Y; Roche H; Fumoleau P; Kerbrat P; Genot JY; Fargeot P; Olivier JP; Fizames C
    J Clin Oncol; 1995 Jul; 13(7):1564-71. PubMed ID: 7541448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma.
    Seymour AM; de Campos E; Thatcher N; De Greve J; Cunningham D; Howell A; Tueni E; Bron DG; Steward WP; Berdel WE
    Eur J Cancer; 1995 Dec; 31A(13-14):2157-63. PubMed ID: 8652235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings.
    Frampton JE; Yarker YE; Goa KL
    Drugs; 1995 May; 49(5):767-93. PubMed ID: 7541335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats.
    Nohynek GJ; Plard JP; Wells MY; Zerial A; Roquet F
    Cancer Chemother Pharmacol; 1997; 39(3):259-66. PubMed ID: 8996530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group.
    Dombret H; Chastang C; Fenaux P; Reiffers J; Bordessoule D; Bouabdallah R; Mandelli F; Ferrant A; Auzanneau G; Tilly H
    N Engl J Med; 1995 Jun; 332(25):1678-83. PubMed ID: 7539109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of lenograstim (glycosylated rHuG-CSF) in the treatment of inflammatory breast cancer for Germany and Italy.
    Mapelli V; Graf vond der Schulenburg JM; Laaser U; Allhoff PG; Rossi F
    Pharmacoeconomics; 1994; 6 Suppl 2():27-35. PubMed ID: 10155593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo-controlled trial in AIDS patients.
    Dubreuil-Lemaire ML; Gori A; Vittecoq D; Panelatti G; Tharaux F; Palisses R; Gharakhanian S; Rozenbaum W;
    Eur J Haematol; 2000 Nov; 65(5):337-43. PubMed ID: 11092465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of recombinant human granulocyte colony stimulating factor (lenograstim) on chemotherapy induced neutropenia in patients with urothelial cancer.
    Kotake T; Usami M; Miki T; Togashi M; Akaza H; Kubota Y; Matsumura Y
    Int J Urol; 1999 Feb; 6(2):61-7. PubMed ID: 10226809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of lenograstim for prophylaxis of chemotherapy-induced neutropenia in patients with small cell lung cancer.
    Drummond M; Davies L
    Pharmacoeconomics; 1994; 6 Suppl 2():44-52. PubMed ID: 10155594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison.
    Toner GC; Shapiro JD; Laidlaw CR; Rischin D; Millward MJ; Wolf M; Januszewicz H; Mitchell SV; Curran AC; Matthews JP; Bishop JF
    J Clin Oncol; 1998 Dec; 16(12):3874-9. PubMed ID: 9850033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenograstim: a review of its use in chemotherapy-induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization.
    Keating GM
    Drugs; 2011 Apr; 71(6):679-707. PubMed ID: 21504247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group.
    Narabayashi M; Takeyama K; Fukutomi T; Tokuda Y; Tajima T; Okumura A; Chou T; Sano M; Makino H; Igarashi T; Sasaki Y; Imoto S; Ogura M; Morishima Y; Murai H; Okamoto S; Ikeda T; Kasai M; Yokozawa T; Tobinai K
    Jpn J Clin Oncol; 1999 Jun; 29(6):285-90. PubMed ID: 10418556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
    Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
    Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.